COST-EFFECTIVENESS OF IDEGLIRA VERSUS BASAL-BOLUS INSULIN INTENSIFICATION REGIMENS IN PATIENTS WITH TYPE 2 DIABETES IN SLOVAK SETTING

被引：0
|
作者：
Psota, M. [1 ]
Racekova, N. [2 ]
Psenkova, M. [1 ]
Vandebrouck, T. [3 ]
Ramirez de Arellano, A. [4 ]
机构：
[1] Pharm In Ltd, Bratislava, Slovakia
[2] Novo Nordisk Slovakia Ltd, Bratislava, Slovakia
[3] Novo Nordisk Hlth Care AG, Brussels, Belgium
[4] Novo Nordisk, Madrid, Spain
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1881
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB51
引用
收藏
页码：A674 / A674
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic
    Kvapil, Milan
    Prazny, Martin
    Holik, Pavel
    Rychna, Karel
    Hunt, Barnaby
    [J]. DIABETES THERAPY, 2017, 8 (06) : 1331 - 1347
  • [2] Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic
    Milan Kvapil
    Martin Prázný
    Pavel Holik
    Karel Rychna
    Barnaby Hunt
    [J]. Diabetes Therapy, 2017, 8 : 1331 - 1347
  • [3] LONG-TERM COST UTILITY ANALYSIS OF IDEGLIRA VERSUS BASAL-BOLUS INSULIN INTENSIFICATION THERAPIES IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON BASAL INSULIN IN SPAIN
    Prades, M.
    Lizan, L.
    Hunt, B.
    Ramirez de Arellano, A.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A99 - A99
  • [4] LONG-TERM COST-EFFECTIVENESS OF IDEGLIRA VERSUS BASAL-BOLUS INSULIN AS INTENSIFICATION THERAPIES FOR PEOPLE WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON BASAL INSULIN IN SPAIN: PROJECTIONS BASED ON THE DUAL VII TRIAL
    Ampudia, F. J.
    Mezquita, P.
    de Arellano, Ramirez A.
    Basse, A.
    Hunt, B.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A480 - A480
  • [5] Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets
    Cannon, Anthony J.
    Bargiota, Alexandra
    Billings, Liana
    Hunt, Barnaby
    Leiter, Lawrence A.
    Malkin, Samuel
    Mocarski, Michelle
    Ranthe, Mattis Flyvholm
    Schiffman, Alisa
    Doshi, Ankur
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (02): : 143 - 153
  • [6] Cost-effectiveness analysis of insulin degludec/liraglutide (IDegLira) vs other basal insulin intensification strategies in Type 2 diabetes patients uncontrolled on basal insulin in a UK setting
    Davies, M.
    McEwan, P.
    Glah, D.
    Chubb, B.
    Konidaris, G.
    Iversen, P.
    [J]. DIABETIC MEDICINE, 2016, 33 : 155 - 155
  • [7] Stepwise intensification of prandial insulin versus basal-bolus insulin therapy in patients with type 2 diabetes mellitus
    Raccah, D.
    Haak, T.
    Huet, D.
    Monnier, L.
    Ramon, J. S.
    Robertson, D.
    Labard, P.
    Penfornis, A.
    [J]. DIABETOLOGIA, 2010, 53
  • [8] Cost-effectiveness of detemir based basal-bolus therapy versus NPH for type 1 diabetes in a Spanish setting
    Ray, J. A.
    Valentine, W. J.
    Goodall, G.
    Aagren, M.
    Kotchie, R. W.
    [J]. DIABETOLOGIA, 2007, 50 : S428 - S428
  • [9] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/INSULIN ASPART TWICE DAILY VERSUS BASAL-BOLUS FULL REGIMEN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN ALGERIA
    Sellam, Y.
    Malek, R.
    Semrouni, M.
    Belhadj, M.
    Zekri, S.
    Brouri, M.
    Arbouche, Z.
    Nouri, N.
    [J]. VALUE IN HEALTH, 2020, 23 : S511 - S511
  • [10] Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting
    Melanie J. Davies
    Divina Glah
    Barrie Chubb
    Gerasimos Konidaris
    Phil McEwan
    [J]. PharmacoEconomics, 2016, 34 : 953 - 966
12345